The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1MHGO4     2-[bis(2-chloroethyl)amino]- 1,3,2...

Synonyms: LS-99823, 4-OH-CP, 67292-62-0
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 4-OH-CP


High impact information on 4-OH-CP


Chemical compound and disease context of 4-OH-CP


Biological context of 4-OH-CP


Anatomical context of 4-OH-CP


Associations of 4-OH-CP with other chemical compounds


Gene context of 4-OH-CP


Analytical, diagnostic and therapeutic context of 4-OH-CP


  1. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. Sandström, M., Freijs, A., Larsson, R., Nygren, P., Fjällskog, M.L., Bergh, J., Karlsson, M.O. J. Clin. Oncol. (1996) [Pubmed]
  2. The influence of the protector thiol L-cystein on the toxic and therapeutic responses of stabilized "activated" cyclophosphamide (4-(S-ethanol)-sulfido-cyclophosphamide). Voelcker, G., Laber, P., Rockinger, H., Wientzek, C., Hohorst, H.J. Investigational new drugs. (1984) [Pubmed]
  3. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. Hassan, M., Nilsson, C., Olsson, H., Lundin, J., Osterborg, A. Eur. J. Haematol. (1999) [Pubmed]
  4. On the cytostatic mechanism of cyclophosphamide. Inhibition of aminoacylation of transfer RNA and induction of stringent control in Escherichia coli by 4-hydroperoxycyclophosphamide. Frank, S., Eck, W., Kersten, W., Ogilvie, A. Hoppe-Seyler's Z. Physiol. Chem. (1981) [Pubmed]
  5. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives. Peter, G., Wagner, T., Hohorst, H.J. Cancer treatment reports. (1976) [Pubmed]
  6. Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: a placebo-controlled clinical trial. Alberts, D.S., Mason-Liddil, N., Plezia, P.M., Roe, D.J., Dorr, R.T., Struck, R.F., Phillips, J.G. J. Natl. Cancer Inst. (1991) [Pubmed]
  7. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Ren, S., Yang, J.S., Kalhorn, T.F., Slattery, J.T. Cancer Res. (1997) [Pubmed]
  8. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin. Kwon, C.H., Maddison, K., LoCastro, L., Borch, R.F. Cancer Res. (1987) [Pubmed]
  9. Mixed function oxidase activities of established human colon carcinoma cell lines in the activation of cyclophosphamide. Moskwa, P.S., Vadi, H., Drewinko, B. Cancer Res. (1985) [Pubmed]
  10. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers. Low, J.E., Borch, R.F., Sladek, N.E. Cancer Res. (1983) [Pubmed]
  11. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Hassan, M., Svensson, U.S., Ljungman, P., Björkstrand, B., Olsson, H., Bielenstein, M., Abdel-Rehim, M., Nilsson, C., Johansson, M., Karlsson, M.O. British journal of clinical pharmacology. (1999) [Pubmed]
  12. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation. Voelcker, G., Bielicki, L., Hohorst, H.J. J. Cancer Res. Clin. Oncol. (1997) [Pubmed]
  13. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. De Jonge, M.E., Mathôt, R.A., Van Dam, S.M., Beijnen, J.H., Rodenhuis, S. Cancer Chemother. Pharmacol. (2002) [Pubmed]
  14. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide. Gilbert, D.N., Starr, P., Eubanks, N. Cancer Res. (1977) [Pubmed]
  15. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Ren, S., Kalhorn, T.F., McDonald, G.B., Anasetti, C., Appelbaum, F.R., Slattery, J.T. Clin. Pharmacol. Ther. (1998) [Pubmed]
  16. Synthesis, activation, and cytotoxicity of aldophosphamide analogues. Borch, R.F., Valente, R.R. J. Med. Chem. (1991) [Pubmed]
  17. Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell. Ohtani, T., Nakamura, T., Toda, K., Furukawa, F. FEBS Lett. (2006) [Pubmed]
  18. Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. Pette, M., Gold, R., Pette, D.F., Hartung, H.P., Toyka, K.V. Immunopharmacology (1995) [Pubmed]
  19. Immunomodulating influence of active metabolite of cyclophosphamide on human lymphocyte immunoglobulin biosynthesis in vitro. Górski, A., Nowaczyk, M., Korczak-Kowalska, G., Rowiński, W. Transplantation (1983) [Pubmed]
  20. Interactions between cyclophosphamide and adriamycin metabolism in rats. Dodion, P., Riggs, C.E., Akman, S.R., Tamburini, J.M., Colvin, O.M., Bachur, N.R. J. Pharmacol. Exp. Ther. (1984) [Pubmed]
  21. Activated oxazaphosphorines are transported predominantly by erythrocytes. Highley, M.S., Schrijvers, D., Van Oosterom, A.T., Harper, P.G., Momerency, G., Van Cauwenberghe, K., Maes, R.A., De Bruijn, E.A., Edelstein, M.B. Ann. Oncol. (1997) [Pubmed]
  22. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis. Low, J.E., Borch, R.F., Sladek, N.E. Cancer Res. (1982) [Pubmed]
  23. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. de Jonge, M.E., Huitema, A.D., van Dam, S.M., Rodenhuis, S., Beijnen, J.H. Therapeutic drug monitoring. (2005) [Pubmed]
  24. Analysis of 4-hydroxycyclophosphamide in human blood. Wright, J.E., Tretyakov, O., Ayash, L.J., Elias, A., Rosowsky, A., Frei, E. Anal. Biochem. (1995) [Pubmed]
  25. Human CYP2B6: expression, inducibility and catalytic activities. Gervot, L., Rochat, B., Gautier, J.C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., Martin, H., Beaune, P., de Waziers, I. Pharmacogenetics (1999) [Pubmed]
  26. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Griskevicius, L., Yasar, U., Sandberg, M., Hidestrand, M., Eliasson, E., Tybring, G., Hassan, M., Dahl, M.L. Eur. J. Clin. Pharmacol. (2003) [Pubmed]
  27. Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Morrow, C.S., Smitherman, P.K., Townsend, A.J. Biochem. Pharmacol. (1998) [Pubmed]
  28. Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard. Qiu, R., Yao, A., Vicini, P., McDonald, G.B., Batchelder, A.L., Bouvier, M.E., Cole, S.L., Slattery, J.T. Clin. Pharmacol. Ther. (2004) [Pubmed]
  29. Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma. Griskevicius, L., Meurling, L., Hassan, M. Therapeutic drug monitoring. (2002) [Pubmed]
  30. Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat. Lu, H., Chan, K.K. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  31. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Ding, Q., Kestell, P., Baguley, B.C., Palmer, B.D., Paxton, J.W., Muller, G., Ching, L.M. Cancer Chemother. Pharmacol. (2002) [Pubmed]
WikiGenes - Universities